FDA's NDA And BLA Approvals: Cotempla XR-ODT, Baxdela, Mydayis, Rituxan Hycela, Haegarda
Original new drugs and biologics recently approved by US FDA.
You may also be interested in...
Bristol will pay $105m up front and as much as $1.76bn in milestone fees to use the Enhanze technology in drugs against up to 11 immuno-oncology targets. Also, Roche will pay up to $190m to add a target to an existing partnership.
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
The merger with Baxalta left Shire a portfolio consisting of 80% rare disease therapies, suggesting logically that the company might want to exit the primary care ADHD space.